Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

HanchorBio Announces Approval for Multi-Regional Clinical Trial of HCB101

Tuesday, July 25, 2023

HanchorBio has received approval from the Taiwan Food and Drug Administration (TFDA) for its investigational new drug (IND) application, enabling them to proceed with a multi-regional clinical trial of their novel drug candidate, HCB101. This drug is being developed to treat patients with advanced solid tumours or relapsed and refractory non-Hodgkin lymphoma.

HCB101 is created using structure-guided protein design and engineering, along with relevant screening technologies. It consists of an engineered extracellular domain of SIRPα fused to the Fc region of IgG4.

This innovative drug works by triggering the phagocytic activity of macrophages, blocking the "do not eat" signal between macrophages and tumour cells. The extensive in-vitro and in-vivo preclinical data suggest that HCB101 could be a safer and more potent biologic compared to the anti-CD47 monoclonal antibodies and SIRPa fusion proteins currently under investigation in clinical trials.

The clinical trial, known as HCB101-101, will be a multi-regional, multi-centre, open-label, dose-finding, first-in-human (FIH) study involving adults with advanced solid tumours or relapsed and refractory non-Hodgkin lymphoma in both the United States and Taiwan. The primary objectives of this study are to assess the safety, tolerability, pharmacokinetics, and clinical anti-tumour activity of weekly HCB101 intravenous injections.



magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024